A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471 · Recruiting

Last updated 2026-05-28

This study is testing the safety and effects of the medication Orforglipron (LY3502970) in adults who have obesity or overweight and knee osteoarthritis.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 800 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2028-05

Where 95 sites · Canada, China, Germany, India, Japan, Mexico, Spain, United States

What this study is testing ClinicalTrials.gov NCT07153471 ↗

Description as written by the study sponsor.

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

Treatments tested

Orforglipron also known as (LY3502970) Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Sponsor	Eli Lilly and Company
Conditions studied	Osteoarthritis
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07153471 ↗